Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2007 1
2009 3
2010 1
2011 3
2012 1
2014 1
2017 1
2022 2
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Long-term complete remission in a patient with high-risk primary mediastinal B-cell lymphoma and iatrogenic symptomatic bradycardia after only two courses of DA-EPOCH-R followed by chemo-free treatment.
Volzone F, Becchimanzi C, Crisci S, De Chiara A, Porto A, Caronna A, Cuccaro A, Sarno S, Mallardo D, Cagini L, De Filippi R, Pinto A. Volzone F, et al. Among authors: becchimanzi c. Ann Hematol. 2024 Nov;103(11):4759-4764. doi: 10.1007/s00277-024-05994-4. Epub 2024 Sep 12. Ann Hematol. 2024. PMID: 39264432
Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study.
De Filippi R, Marcacci G, Derenzini E, Musso M, Donnarumma D, Morelli E, Patti C, Maraglino AME, Scalone R, Simeone L, Becchimanzi C, Mele S, Crisci S, Morabito F, Pinto A. De Filippi R, et al. Among authors: becchimanzi c. Cancers (Basel). 2022 Nov 27;14(23):5846. doi: 10.3390/cancers14235846. Cancers (Basel). 2022. PMID: 36497328 Free PMC article.
A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, Pinto A. Russo F, et al. Among authors: becchimanzi c. Br J Haematol. 2014 Jul;166(1):118-29. doi: 10.1111/bjh.12862. Epub 2014 Mar 27. Br J Haematol. 2014. PMID: 24673727 Clinical Trial.
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
Corazzelli G, Capobianco G, Arcamone M, Ballerini PF, Iannitto E, Russo F, Frigeri F, Becchimanzi C, Marcacci G, De Chiara A, Pinto A. Corazzelli G, et al. Among authors: becchimanzi c. Cancer Chemother Pharmacol. 2009 Oct;64(5):907-16. doi: 10.1007/s00280-009-0941-9. Epub 2009 Feb 15. Cancer Chemother Pharmacol. 2009. PMID: 19219604
Elevation of clonal serum free light chains in patients with HIV-negative primary effusion lymphoma (PEL) and PEL-like lymphoma.
De Filippi R, Iaccarino G, Frigeri F, Di Francia R, Crisci S, Capobianco G, Arcamone M, Becchimanzi C, Amoroso B, De Chiara A, Corazzelli G, Pinto A. De Filippi R, et al. Among authors: becchimanzi c. Br J Haematol. 2009 Nov;147(3):405-8. doi: 10.1111/j.1365-2141.2009.07846.x. Epub 2009 Aug 13. Br J Haematol. 2009. PMID: 19681885 No abstract available.
Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.
Corazzelli G, Frigeri F, Arcamone M, Aloj L, Capobianco G, Becchimanzi C, Morelli E, Volzone F, Marcacci G, Russo F, De Filippi R, Lastoria S, Pinto A. Corazzelli G, et al. Among authors: becchimanzi c. Eur J Haematol. 2011 Dec;87(6):547-53. doi: 10.1111/j.1600-0609.2011.01683.x. Epub 2011 Jul 31. Eur J Haematol. 2011. PMID: 21752099 Free PMC article.
16 results